Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.57 |
| ▸ | FAAH | O00519 | 7/20 | 0.56 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.54 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.53 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16860733 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL16860699 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL29215544 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL25284318 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL29215585 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL25052917 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL29875541 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| Hydrochloric Acid SCHEMBL31297529 | 0.98 | NOD1 (0.56) | NOD1FAAHASAH1P2RY10GPR174 | |
| Hydrochloric Acid SCHEMBL29215303 | 0.98 | NOD1 (0.56) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL16860735 | 0.98 | NOD1 (0.55) | NOD1FAAHASAH1P2RY10GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076582-A | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX生物治疗股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-118076582-A | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX生物治疗股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | NOD1 290/4885FAAH 4058/4885ASAH1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.